Fig. 5: Efficacy of CAB ISFI against rectal SHIV infection in rhesus macaques. | Nature Communications

Fig. 5: Efficacy of CAB ISFI against rectal SHIV infection in rhesus macaques.

From: Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection

Fig. 5

a Short-term protection by CAB ISFIs. Two CAB treated (RH-1093 and RH-1097) and one untreated macaque (RH-1092) were exposed rectally to SHIV between weeks 4 and 8 post implantation. Each animal received rectal SHIV challenges twice per week for up to 4 weeks (total of eight exposures). Arrows indicate SHIV exposures. ISFIs were surgically removed at week 12 (blue and purple solid circles) b Plasma SHIV RNA levels detected by real-time PCR in animals during challenge period and 32-week follow-up period. c Long-term protection by CAB ISFI. Two CAB treated (RH-1080 and RH-1048) and one untreated macaque (RH-1084) received rectal SHIV challenges twice per week between weeks 14 and 18 post implantation (up to 8 exposures). Animal RH-1048 received six additional SHIV challenges between weeks 25 and 28 (total of 14 exposures). Arrows indicate SHIV exposures. d Plasma SHIV RNA levels detected by real-time PCR in animals during the challenge period and the 24- to 36-week follow-up period.

Back to article page